Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of BMAC Enhanced CABG

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age\> 18 years and ability to understand the planned treatment.~* Patients with ischemic congestive heart failure requiring by pass surgery~* Congestive heart failure with ejection fraction ≤ 40%.~* Serum bilirubin, SGOT and SGPT ≤2.5 time the upper level of normal.~* Serum creatinine \< 3.0 or no dialysis.~* NYHA performance status ≥ 3.~* Negative pregnancy test (in women with childbearing potential).~* Subject has read and signed the IRB approved Informed Consent form~* Hematocrit ≥ 28.0%, White Blood Cell count ≤ 14,000, Platelet count ≥ 50,000, Creatinine ≤ 3.0 mg / Dl, and/or no dialysis, INR ≤ 1.6 unless on Coumadin, or PTT \<1.5 x control (to avoid bleeding complications) Patients on Coumadin will be corrected prior to the procedure and must have an INR\<1.6 at the time of randomization/surgery~Exclusion Criteria:~* Female who is pregnant or nursing, or of child bearing potential and is not using a reliable birth control method, or who intend to become pregnant during the tenure of this study.~* History of Prior Radiation Exposure for oncological treatment.~* History of Bone Marrow Disorder (especially NHL, MDS) that prohibit transplantation.~* History of abnormal Bleeding or Clotting.~* History of Liver Cirrhosis.~* Acute Myocardial Infarction \< 4 weeks from treatment date.~* Known active malignancy or results outside of normal limits from the following tests: PAP, Chest X-ray, PSA, Mammogram, Hemoccult unless follow-up studies reveal patient to be cancer free.~* Active clinical infection being treated by antibiotics within one week of enrollment~* Terminal renal failure with existing dependence on dialysis~* Inability or unwillingness to comply with the treatment protocol, follow-up, research tests, or give consent.~* Unable to have 250cc bone marrow harvested.~* Medical risk that precludes anesthesia or ASA Class 5~* History of ventricular arrhythmia if AICD is not present.~* History of ventricular aneurysm.~* Concurrent surgery such as CABG with valve surgery.~* Minimally Invasive bypass surgery~* Life expectancy \<6 months due to concomitant illnesses~* Treatment with immunosuppressant drugs (including Prednisone \> 5 mg per day)~* Patients undergoing urgent by pass surgical procedure~* Patients with HGB A1C \> 8.5%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): CABG only
- BMAC enhanced CABG (Type: EXPERIMENTAL): Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).